Daidzein
Research reviewed: Up until 03/2026
Daidzein is a dietary supplement with 8 published peer-reviewed studies involving 1,280 participants, researched for Bone Health, Menopause Symptoms, Metabolic Health and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Bone Health
ModerateMenopause Symptoms
ModerateMetabolic Health
ModerateCardiovascular Health
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Bone Health
To evaluate Daidzein supplementation on bone mineral density and turnover markers in postmenopausal women
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Daidzein supplementation on bone mineral density and turnover markers in postmenopausal women
Dose
150 mg Daidzein-rich isoflavone daily
Participants
180 postmenopausal women
Duration
2 years
Results
Daidzein significantly reduced CTX levels and preserved lumbar spine BMD compared to placebo. Effects were strongest in women who converted Daidzein to Equol. Femoral neck BMD changes not significant.
How They Measured It
DXA scan, CTX (bone resorption marker), P1NP (bone formation marker), osteocalcin
To examine the phytoestrogenic mechanisms of Daidzein in preserving bone in ovariectomized rats
Study Type
Animal study
Purpose
To examine the phytoestrogenic mechanisms of Daidzein in preserving bone in ovariectomized rats
Dose
10-100 mg/kg Daidzein
Participants
36 ovariectomized rats
Duration
12 weeks
Results
Daidzein preserved BMD and trabecular bone architecture, stimulated osteoblast activity via ER-β, suppressed osteoclastogenesis, and reduced bone resorption markers. Uterotrophic effects were minimal compared to estradiol.
How They Measured It
BMD by DXA, bone histomorphometry, osteoblast/osteoclast markers, ER-β receptor binding
Menopause Symptoms
To evaluate Daidzein and Genistein combination on menopausal symptoms and quality of life
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Daidzein and Genistein combination on menopausal symptoms and quality of life
Dose
Daidzein 90 mg + Genistein 54 mg daily
Participants
265 postmenopausal women
Duration
12 weeks
Results
Combined Daidzein/Genistein supplementation significantly reduced hot flush frequency (−40% vs −19% placebo), improved Greene Climacteric scores, and enhanced quality of life. Equol producers showed greatest benefits.
How They Measured It
Hot flush frequency/severity, Greene Climacteric Scale, MENQOL, sleep quality
Metabolic Health
To evaluate Daidzein-rich isoflavone supplementation on body composition and metabolic health in overweight postmenopausal women
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Daidzein-rich isoflavone supplementation on body composition and metabolic health in overweight postmenopausal women
Dose
150 mg Daidzein isoflavones daily
Participants
160 overweight postmenopausal women
Duration
6 months
Results
Daidzein isoflavones significantly reduced body fat mass (−1.4 kg), waist circumference, fasting insulin, and improved adiponectin levels compared to placebo. Effects on glucose and HbA1c were modest.
How They Measured It
Body fat mass (DXA), waist circumference, insulin, fasting glucose, adipokines
To investigate metabolic effects of Daidzein on adipocyte differentiation and lipid metabolism
Study Type
Animal study
Purpose
To investigate metabolic effects of Daidzein on adipocyte differentiation and lipid metabolism
Dose
10-100 μM Daidzein (cell), 50 mg/kg (animal)
Participants
3T3-L1 preadipocytes and 20 obese mice
Duration
Differentiation protocol/8 weeks
Results
Daidzein modestly inhibited adipocyte differentiation at high concentrations, reduced lipid accumulation, increased adiponectin secretion, and activated AMPK in adipocytes. In vivo data confirmed modest anti-obesity effects.
How They Measured It
Adipogenesis, PPAR-γ/C/EBPα expression, lipid accumulation, adipokine secretion, AMPK pathway
Cardiovascular Health
To determine the effect of soy isoflavones including Daidzein on lipid profiles in postmenopausal women
Study Type
Meta-analysis
Purpose
To determine the effect of soy isoflavones including Daidzein on lipid profiles in postmenopausal women
Dose
Daidzein-containing soy isoflavone formulations
Participants
Meta-analysis of 14 RCTs (n=741)
Duration
Various
Results
Soy isoflavones (Daidzein primary component) significantly reduced LDL (−0.15 mmol/L) and triglycerides (−0.12 mmol/L) and modestly increased HDL (+0.04 mmol/L). Effects were consistent across multiple studies.
How They Measured It
Meta-analysis of lipid outcomes (LDL, HDL, TG) from RCTs
To evaluate the vasoprotective and anti-platelet mechanisms of Daidzein
Study Type
In vitro study
Purpose
To evaluate the vasoprotective and anti-platelet mechanisms of Daidzein
Dose
0.1-10 μM Daidzein
Participants
Human platelets, endothelial cells, vascular smooth muscle cells
Duration
2-24 hours
Results
Daidzein inhibited platelet aggregation, stimulated eNOS/NO via ER-β, and suppressed VSMC proliferation triggered by PDGF, demonstrating multiple vasoprotective mechanisms at physiologically relevant concentrations.
How They Measured It
Platelet aggregation, TXA2, eNOS expression, VSMC proliferation, ER-β activation
To evaluate the evidence for Daidzein in menopausal symptoms, bone health, and cardiovascular risk reduction
Study Type
Systematic review
Purpose
To evaluate the evidence for Daidzein in menopausal symptoms, bone health, and cardiovascular risk reduction
Dose
Daidzein mono or combination formulations
Participants
Review of 35 clinical studies
Duration
Various
Results
Daidzein shows consistent benefits for menopausal symptom relief, bone preservation, and cardiovascular risk reduction in postmenopausal women. Equol producer status is a critical factor for clinical response. Larger trials needed.
How They Measured It
Systematic review and meta-analysis of RCTs and observational studies
Frequently Asked Questions
Common questions about Daidzein research
There are currently 9 peer-reviewed studies on Daidzein (Daidzein), involving 1,280 total participants. Research covers Bone health, Menopause symptoms, Metabolic health and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (8 human studies), and reported outcomes.
Daidzein has been researched for: Bone health, Menopause symptoms, Metabolic health, Cardiovascular health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 8 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
